NCT05911724Completed
Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.
Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.
Source: ClinicalTrials.gov · Last updated 7 Jan 2025
Brief summary (registry, in English)
The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 180 (actual)
- First submitted
- 10 Jun 2023
- Start date
- 1 Mar 2023
- Primary completion date
- 20 Sept 2024
- Lead sponsor
- Damanhour University
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT05911724
What you commit to
- Study type: Observational
- Participants enrolled: 180
- From 1 Mar 2023 to the primary completion date, 20 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- major trauma or surgical operation over the past three months.
Other illness
- severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.);
- malignant tumor;
- acute/ chronic infectious diseases;
- autoimmune disease or connective tissue disease;
Other
- severe liver/
- kidney dysfunction;
Who the study is looking for
- Either sex, aged 18 years or older.
- new-onset AHF or acute decompensation of chronic HF,
- CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more).
- On empagliflozin 10 mg once daily for 6 months before the beginning of the study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta University Hospital Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.